Ubs Asset Management Americas Inc Immunovant, Inc. Transaction History

Ubs Asset Management Americas Inc

  • $446 Billion
  • Q3 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Immunovant, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 107,224 shares of IMVT stock, worth $2.95 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
107,224
Previous 200,260 46.46%
Holding current value
$2.95 Million
Previous $5.51 Million 46.47%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
SELL
N/A
-93,036 Reduced 46.46%
107,224 $2.95 Million
Q2 2025

Aug 14, 2025
BUY
N/A
60,169 Added 42.95%
200,260 $5.51 Million
Q1 2025

May 19, 2025
SELL
N/A
-139,161 Reduced 49.83%
140,091 $3.85 Million
Q4 2024

Feb 14, 2025
SELL
N/A
-31,578 Reduced 10.16%
279,252 $7.68 Million
Q3 2024

Nov 14, 2024
SELL
$27.51 - $27.51 $266,241 - $266,241
-9,678 Reduced 3.02%
310,830 $8.55 Million
Q2 2024

Aug 13, 2024
BUY
$25.1 - $31.61 $2.87 Million - $3.62 Million
114,477 Added 55.56%
320,508 $8.46 Million
Q1 2024

May 15, 2024
SELL
$30.27 - $43.79 $46,040 - $66,604
-1,521 Reduced 0.73%
206,031 $6.66 Million
Q4 2023

Feb 14, 2024
BUY
$31.31 - $44.19 $3.9 Million - $5.51 Million
124,636 Added 150.32%
207,552 $8.74 Million
Q3 2023

Nov 13, 2023
BUY
$18.55 - $39.96 $578,648 - $1.25 Million
31,194 Added 60.31%
82,916 $3.18 Million
Q1 2023

May 15, 2023
BUY
$15.27 - $19.72 $121,671 - $157,128
7,968 Added 18.21%
51,722 $802,000
Q4 2022

Feb 14, 2023
BUY
$6.59 - $17.75 $42,235 - $113,759
6,409 Added 17.16%
43,754 $776,000
Q3 2022

Nov 14, 2022
SELL
$3.93 - $6.37 $57,366 - $92,982
-14,597 Reduced 28.1%
37,345 $208,000
Q3 2021

Nov 15, 2021
SELL
$7.01 - $11.37 $57,867 - $93,859
-8,255 Reduced 13.71%
51,942 $451,000
Q2 2021

Aug 16, 2021
BUY
$9.4 - $16.85 $156,510 - $280,552
16,650 Added 38.23%
60,197 $636,000
Q1 2021

May 14, 2021
SELL
$13.08 - $49.6 $14,309 - $54,262
-1,094 Reduced 2.45%
43,547 $698,000
Q4 2020

Mar 01, 2021
BUY
$36.36 - $52.71 $895,946 - $1.3 Million
24,641 Added 123.21%
44,641 $2.06 Million
Q3 2020

Nov 13, 2020
BUY
$22.61 - $38.9 $250,971 - $431,790
11,100 Added 124.72%
20,000 $703,000
Q2 2020

Aug 14, 2020
BUY
$13.87 - $28.44 $123,443 - $253,116
8,900 New
8,900 $216,000

Others Institutions Holding IMVT

# of Institutions
214
Shares Held
81.1M
Call Options Held
597K
Put Options Held
704K
View Full List

About Immunovant, Inc.

IMVT Quotes by TradingView
  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email